The most important financial indicators for the company Inga Prima Pharma Srl - Unique Identification Number 28111360:
sales in 2023 was
39.862
euro, registering a net profit of
8.551
euro and having an average number of
1
employees.
Firma isi desfasoara activitatea in domeniul Facilitati de cazare pentru vacante si perioade de scurta durata having the NACE code 5520.
Sales, Profit, Employees, Debts, Capitals, Financial Results -
Inga Prima Pharma Srl
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Sales - EUR
9.398
14.177
20.619
16.036
29.090
25.539
36.943
37.123
52.404
39.862
Total Income - EUR
9.407
14.194
20.629
16.040
29.090
25.592
37.003
37.128
52.409
40.232
Total Expenses - EUR
4.381
11.700
9.744
7.275
8.002
9.234
9.684
13.911
17.272
31.327
Gross Profit/Loss - EUR
5.027
2.494
10.884
8.765
21.088
16.359
27.319
23.218
35.137
8.905
Net Profit/Loss - EUR
4.744
2.068
10.265
8.284
20.215
15.936
26.363
22.309
34.038
8.551
Employees
0
0
0
0
0
0
0
0
1
1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.
In the last year of activity, the sales decreased by -23.7%, from 52.404 euro in the year 2022, to 39.862 euro in 2023.
The Net Profit decreased by -25.383 euro, from 34.038 euro in 2022, to 8.551 in the last year.
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Inga Prima Pharma Srl - CUI 28111360
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Fixed Assets
2.342
1.826
3.881
2.728
12.603
1.156
662
259
939
1.293
Current Assets
2.809
6.766
8.450
5.613
15.843
14.961
30.726
25.337
34.840
12.489
Inventories
0
0
0
0
0
0
0
0
0
0
Receivables
0
0
0
0
0
84
0
0
32.775
408
Cash
2.809
6.766
8.450
5.613
15.843
14.877
30.726
25.337
2.064
12.081
Shareholders Funds
4.791
6.899
10.319
8.337
28.399
15.987
31.166
22.357
34.086
10.188
Social Capital
45
45
45
44
43
42
41
40
41
40
Debts
361
1.694
2.013
4
4
67
181
290
1.693
3.638
Income in Advance
0
0
0
0
43
63
41
2.948
0
0
Exchange rate - RON
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
4.4821
Main CAEN
"5520 - 5520"
CAEN Financial Year
5520
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
12.489 euro in 2023 which includes Inventories of
0 euro, Receivables of
408 euro and cash availability of
12.081 euro.
The company's Equity was valued at
10.188 euro, while total Liabilities amounted to
3.638 euro.
Equity decreased by -23.795 euro, from 34.086 euro in 2022, to 10.188 in 2023.
Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Inga Prima Pharma Srl